EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Oral glucocorticoids and risk of psychiatric and suicidal behaviour outcomes: population-based cohort study

Tyra Lagerberg iD, Tapio T Gustafsson, Yasmina Molero, Julian Forton, Amir Sariaslan, Zheng Chang, Henrik Larsson, Paul Lichtenstein, Seena Fazel iD

The British Journal of Psychiatry · 2026-07 · 229 (1) · 43-50

DOI: 10.1192/bjp.2025.128 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift The British Journal of Psychiatry, online erschienen am 25.06.2025. Verfasst von Tyra Lagerberg und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Warneford Hospital, University of Oxford, UK. Hauptthemen laut MEDLINE: Glucocorticoids, Mental Disorders, Suicide. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite evidence of associations between glucocorticoid treatment and adverse psychiatric and suicidal behaviour outcomes, large-scale observational evidence for serious outcomes is lacking.

Aims

To assess the risk of psychiatric and suicidal behaviour outcomes during glucocorticoid treatment.

Method

Using Swedish population registers, we identified 1 105 964 individuals aged 15–54 years who collected a glucocorticoid prescription in oral form between 2006 and 2020. We investigated associations with a range of psychiatric outcomes: unplanned specialist healthcare contacts due to depressive, bipolar, anxiety or schizophrenia-spectrum disorders; and deaths by suicide or unplanned specialist healthcare contacts due to self-harm (‘suicidal behaviour’). We estimated hazard ratios from Cox proportional hazards models in a medication-only cohort by comparing outcome rates during and outside treated periods within individuals. We further identified individuals with an autoimmune or gastrointestinal autoimmune disorder diagnosis and compared hazards of the outcomes between those who did and did not initiate a glucocorticoid using a target trial emulation approach.

Results

We found increased risks for psychiatric outcomes, with within-individual hazard ratios ranging from 1.08 (95% CI, 1.00–1.16) for depressive disorders to 1.23 (95% CI, 1.12–1.36) for bipolar disorder and 1.25 (95% CI, 1.20–1.31) for anxiety disorders. We found no clear association with suicidal behaviour (hazard ratio: 1.06; 95% CI, 0.96–1.17). These findings were similar when stratified by age and gender. Within-individual associations were attenuated in those diagnosed with an autoimmune disorder. The risk of anxiety and bipolar disorder outcomes appeared particularly elevated in the first weeks of treatment. Absolute rates were modestly elevated during treatment, and higher in those with a history of psychiatric disorders.

Conclusions

Glucocorticoid treatment is associated with elevated risks of serious psychiatric outcomes, including the onset and relapse of common psychiatric disorders. Individuals with psychiatric histories may require additional monitoring during glucocorticoid treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucocorticoidsMental DisordersSuicideHumansAdultFemaleMaleMiddle AgedSwedenAdolescentYoung AdultCohort StudiesAdministration, OralRegistriesRisk FactorsProportional Hazards Models

Stichwörter der Autor:innen

Bipolar disordercorticosteroiddepressionpharmacoepidemiologysuicidal behaviour

Substanzen

Glucocorticoids

Autor:innen und Institutionen

  • Department of Psychiatry, Warneford Hospital, University of Oxford, UK.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden.
  • Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
  • Department of Clinical Neuroscience, Karolinska Institutet, Sweden.
  • The Children's Hospital for Wales, Cardiff, UK.
  • Cardiff University School of Medicine, UK.

ORCID-Profile: Tyra Lagerberg, Seena Fazel

Förderung

  • Wellcome Trust

Zitieren

APA

Lagerberg, T., Gustafsson, T. T., Molero, Y., Forton, J., Sariaslan, A., Chang, Z., Larsson, H., Lichtenstein, P., & Fazel, S. (2026). Oral glucocorticoids and risk of psychiatric and suicidal behaviour outcomes: population-based cohort study. The British Journal of Psychiatry, 229(1), 43-50. https://doi.org/10.1192/bjp.2025.128

Vancouver

Lagerberg T, Gustafsson TT, Molero Y, Forton J, Sariaslan A, Chang Z, et al. Oral glucocorticoids and risk of psychiatric and suicidal behaviour outcomes: population-based cohort study. The British Journal of Psychiatry. 2026;229(1):43-50. doi:10.1192/bjp.2025.128

BibTeX
@article{Lagerberg2026,
  author = {Lagerberg, Tyra and Gustafsson, Tapio T and Molero, Yasmina and Forton, Julian and Sariaslan, Amir and Chang, Zheng and Larsson, Henrik and Lichtenstein, Paul and Fazel, Seena},
  title = {Oral glucocorticoids and risk of psychiatric and suicidal behaviour outcomes: population-based cohort study},
  journal = {The British Journal of Psychiatry},
  year = {2026},
  volume = {229},
  number = {1},
  pages = {43--50},
  doi = {10.1192/bjp.2025.128}
}
Kostenlos starten →